Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

MLA

Satoshi Matsusaka, et al. “Cetuximab Treatment for Metastatic Colorectal Cancer with KRAS p.G13D Mutations Improves Progression-Free Survival.” Molecular and Clinical Oncology, vol. 3, July 2015, pp. 1053–57. EBSCOhost, https://doi.org/10.3892/mco.2015.602.

APA

Satoshi Matsusaka, Nobuyuki Mizunuma, Yoshimasa Kawazoe, Keisho Chin, Yosuke Kumekawa, Mitsukuni Suenaga, Takaharu Misaka, Takashi Goto, Masato Ozaka, Masaru Oba, Hiroki Osumi, Hitomi Kamo, Kiyohiko Hatake, Mariko Ogura, Masahiko Osako, & Eiji Shinozaki. (2015). Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and Clinical Oncology, 3, 1053–1057. https://doi.org/10.3892/mco.2015.602

Chicago

Satoshi Matsusaka, Nobuyuki Mizunuma, Yoshimasa Kawazoe, Keisho Chin, Yosuke Kumekawa, Mitsukuni Suenaga, Takaharu Misaka, et al. 2015. “Cetuximab Treatment for Metastatic Colorectal Cancer with KRAS p.G13D Mutations Improves Progression-Free Survival.” Molecular and Clinical Oncology 3 (July): 1053–57. doi:10.3892/mco.2015.602.